secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2026-03-25T23:59:59+00:00
Accession:  0001601830-26-000054
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion appoints Vicki Goodman as CMO effective April 6, 2026; David Mauro transitions out
--------------------------------------------------------------------------------

- Dr. Goodman joins from Mural Oncology as CMO; prior executive roles at Exelixis, Merck, BMS, and GSK.
- Outgoing CMO Dr. Mauro will serve as advisor until May 29, 2026, after three years at Recursion.
- CEO Najat Khan highlights Goodman's late-stage clinical development experience for advancing pipeline.
- Company reiterates key clinical and regulatory milestones consistent with prior expectations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183026000054/0001601830-26-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183026000054/rxrx-20260325.htm
  HTML page:      https://secwatch.observer/filing/0001601830-26-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer